cover image: Human Papillomavirus and Considerations for Prevention Post-COVID-19  - March 2023

20.500.12592/q3wjcq

Human Papillomavirus and Considerations for Prevention Post-COVID-19 - March 2023

25 May 2023

Understanding HPV and the cause of cervical cancer has led to major advances in the primary and secondary prevention of cervical cancer. [...] They are to complete HPV vaccination of 90% of girls by the age of 15 years, screening of 70% of women by the age of 35 years and then by 45 years, and treatment of 90% of women diagnosed with cervical disease, including both women with cervical pre-cancer and women with invasive malignancy [18, 29, 40-42]. [...] There are three HPV vaccines authorized for use in Canada: the bivalent vaccine "Cervarix®" (HPV2) contains the VLPs of HPV16 and 18, the two types that cause 70% of cervical cancer worldwide and even greater proportions of HPV-associated vulvar, vaginal, penile, anal, and oropharyngeal cancers. [...] The Impact of the COVID-19 Pandemic and HPV prevention As with many other programs are affected by the COVID-19 pandemic, the number of cervical cancer screening tests and the number of cytological abnormalities identified have also been affected. [...] Because of the COVID vaccine's preventive effects, perceptions of the importance and safety of vaccination are likely to have a positive overall effect on the acceptance of a newly developed vaccine [93].

Authors

Shyama Nanayakkara

Pages
21
Published in
Canada